B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
Identifieur interne : 002875 ( PubMed/Curation ); précédent : 002874; suivant : 002876B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
Auteurs : Xiaofen Zhong [République populaire de Chine] ; Huanghao Yang ; Zu-Feng Guo ; Wan-Yee Fion Sin ; Wei Chen ; Junjie Xu ; Ling Fu ; Jie Wu ; Chun-Kit Gannon Mak ; Chak-Sum Samuel Cheng ; Yanzhen Yang ; Shuyong Cao ; Tin-Yau Wong ; Sik-To Lai ; Yong Xie ; Zhihong GuoSource :
- Journal of virology [ 0022-538X ] ; 2005.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Antigènes viraux (immunologie), Banque de peptides, Cartographie épitopique, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Hong Kong, Humains, Lymphocytes B (immunologie), Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (immunologie), Protéines virales (immunologie), Protéines virales non structurales, Sujet âgé, Syndrome respiratoire aigu sévère (immunologie), Tests de neutralisation, Virus du SRAS (immunologie), Épitopes immunodominants.
- MESH :
- immunologie : Antigènes viraux, Glycoprotéines membranaires, Lymphocytes B, Protéines de l'enveloppe virale, Protéines nucléocapside, Protéines virales, Syndrome respiratoire aigu sévère, Virus du SRAS.
- sang : Anticorps antiviraux.
- Adulte, Adulte d'âge moyen, Banque de peptides, Cartographie épitopique, Glycoprotéine de spicule des coronavirus, Hong Kong, Humains, Protéines virales non structurales, Sujet âgé, Tests de neutralisation, Épitopes immunodominants.
- Wicri :
- geographic : Hong Kong.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Viral (blood), Antigens, Viral (immunology), B-Lymphocytes (immunology), Epitope Mapping, Hong Kong, Humans, Immunodominant Epitopes, Membrane Glycoproteins (immunology), Middle Aged, Neutralization Tests, Nucleocapsid Proteins (immunology), Peptide Library, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (immunology), Viral Nonstructural Proteins, Viral Proteins (immunology).
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Antigens, Viral, Membrane Glycoproteins, Nucleocapsid Proteins, Viral Envelope Proteins, Viral Proteins.
- geographic : Hong Kong, Immunodominant Epitopes, Peptide Library, Spike Glycoprotein, Coronavirus, Viral Nonstructural Proteins.
- immunology : B-Lymphocytes, SARS Virus, Severe Acute Respiratory Syndrome.
- Adult, Aged, Epitope Mapping, Humans, Middle Aged, Neutralization Tests.
Abstract
Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel strain of coronavirus. Examination of the immune responses of patients who have recovered from SARS should provide important information for design of a safe and effective vaccine. We determined the continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS patients through biopanning with a vast M13 phage display dodecapeptide library. These epitopes converged to very short peptide fragments, one on each of the structural proteins spike and nucleocapsid and the nonstructural proteins 3a, 9b, and nsp 3. Immunoassays found that most of the patients who had recovered from SARS developed complementary antibodies to the epitope-rich region on the spike S2 protein, indicating that this is an immunodominant site on the viral envelope comprising the spike, matrix, and small envelope glycoproteins. These S2-targeting antibodies were shown to effectively neutralize the coronavirus, indicating that they provided protective immunity to help the patients recover from the viral infection. These results suggest that the SARS coronavirus might have an antigenic profile distinct from those of other human or animal coronaviruses. Due to the tested safety and protective effects of the convalescent-phase serological antibodies, identification of their complementary antigens may enable the design of an epitope-based vaccine to prevent potential antibody-mediated immunopathology.
DOI: 10.1128/JVI.79.6.3401-3408.2005
PubMed: 15731234
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002875
Links to Exploration step
pubmed:15731234Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.</title><author><name sortKey="Zhong, Xiaofen" sort="Zhong, Xiaofen" uniqKey="Zhong X" first="Xiaofen" last="Zhong">Xiaofen Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR</wicri:regionArea></affiliation></author><author><name sortKey="Yang, Huanghao" sort="Yang, Huanghao" uniqKey="Yang H" first="Huanghao" last="Yang">Huanghao Yang</name></author><author><name sortKey="Guo, Zu Feng" sort="Guo, Zu Feng" uniqKey="Guo Z" first="Zu-Feng" last="Guo">Zu-Feng Guo</name></author><author><name sortKey="Sin, Wan Yee Fion" sort="Sin, Wan Yee Fion" uniqKey="Sin W" first="Wan-Yee Fion" last="Sin">Wan-Yee Fion Sin</name></author><author><name sortKey="Chen, Wei" sort="Chen, Wei" uniqKey="Chen W" first="Wei" last="Chen">Wei Chen</name></author><author><name sortKey="Xu, Junjie" sort="Xu, Junjie" uniqKey="Xu J" first="Junjie" last="Xu">Junjie Xu</name></author><author><name sortKey="Fu, Ling" sort="Fu, Ling" uniqKey="Fu L" first="Ling" last="Fu">Ling Fu</name></author><author><name sortKey="Wu, Jie" sort="Wu, Jie" uniqKey="Wu J" first="Jie" last="Wu">Jie Wu</name></author><author><name sortKey="Mak, Chun Kit Gannon" sort="Mak, Chun Kit Gannon" uniqKey="Mak C" first="Chun-Kit Gannon" last="Mak">Chun-Kit Gannon Mak</name></author><author><name sortKey="Cheng, Chak Sum Samuel" sort="Cheng, Chak Sum Samuel" uniqKey="Cheng C" first="Chak-Sum Samuel" last="Cheng">Chak-Sum Samuel Cheng</name></author><author><name sortKey="Yang, Yanzhen" sort="Yang, Yanzhen" uniqKey="Yang Y" first="Yanzhen" last="Yang">Yanzhen Yang</name></author><author><name sortKey="Cao, Shuyong" sort="Cao, Shuyong" uniqKey="Cao S" first="Shuyong" last="Cao">Shuyong Cao</name></author><author><name sortKey="Wong, Tin Yau" sort="Wong, Tin Yau" uniqKey="Wong T" first="Tin-Yau" last="Wong">Tin-Yau Wong</name></author><author><name sortKey="Lai, Sik To" sort="Lai, Sik To" uniqKey="Lai S" first="Sik-To" last="Lai">Sik-To Lai</name></author><author><name sortKey="Xie, Yong" sort="Xie, Yong" uniqKey="Xie Y" first="Yong" last="Xie">Yong Xie</name></author><author><name sortKey="Guo, Zhihong" sort="Guo, Zhihong" uniqKey="Guo Z" first="Zhihong" last="Guo">Zhihong Guo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15731234</idno><idno type="pmid">15731234</idno><idno type="doi">10.1128/JVI.79.6.3401-3408.2005</idno><idno type="wicri:Area/PubMed/Corpus">002875</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002875</idno><idno type="wicri:Area/PubMed/Curation">002875</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002875</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.</title><author><name sortKey="Zhong, Xiaofen" sort="Zhong, Xiaofen" uniqKey="Zhong X" first="Xiaofen" last="Zhong">Xiaofen Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR</wicri:regionArea></affiliation></author><author><name sortKey="Yang, Huanghao" sort="Yang, Huanghao" uniqKey="Yang H" first="Huanghao" last="Yang">Huanghao Yang</name></author><author><name sortKey="Guo, Zu Feng" sort="Guo, Zu Feng" uniqKey="Guo Z" first="Zu-Feng" last="Guo">Zu-Feng Guo</name></author><author><name sortKey="Sin, Wan Yee Fion" sort="Sin, Wan Yee Fion" uniqKey="Sin W" first="Wan-Yee Fion" last="Sin">Wan-Yee Fion Sin</name></author><author><name sortKey="Chen, Wei" sort="Chen, Wei" uniqKey="Chen W" first="Wei" last="Chen">Wei Chen</name></author><author><name sortKey="Xu, Junjie" sort="Xu, Junjie" uniqKey="Xu J" first="Junjie" last="Xu">Junjie Xu</name></author><author><name sortKey="Fu, Ling" sort="Fu, Ling" uniqKey="Fu L" first="Ling" last="Fu">Ling Fu</name></author><author><name sortKey="Wu, Jie" sort="Wu, Jie" uniqKey="Wu J" first="Jie" last="Wu">Jie Wu</name></author><author><name sortKey="Mak, Chun Kit Gannon" sort="Mak, Chun Kit Gannon" uniqKey="Mak C" first="Chun-Kit Gannon" last="Mak">Chun-Kit Gannon Mak</name></author><author><name sortKey="Cheng, Chak Sum Samuel" sort="Cheng, Chak Sum Samuel" uniqKey="Cheng C" first="Chak-Sum Samuel" last="Cheng">Chak-Sum Samuel Cheng</name></author><author><name sortKey="Yang, Yanzhen" sort="Yang, Yanzhen" uniqKey="Yang Y" first="Yanzhen" last="Yang">Yanzhen Yang</name></author><author><name sortKey="Cao, Shuyong" sort="Cao, Shuyong" uniqKey="Cao S" first="Shuyong" last="Cao">Shuyong Cao</name></author><author><name sortKey="Wong, Tin Yau" sort="Wong, Tin Yau" uniqKey="Wong T" first="Tin-Yau" last="Wong">Tin-Yau Wong</name></author><author><name sortKey="Lai, Sik To" sort="Lai, Sik To" uniqKey="Lai S" first="Sik-To" last="Lai">Sik-To Lai</name></author><author><name sortKey="Xie, Yong" sort="Xie, Yong" uniqKey="Xie Y" first="Yong" last="Xie">Yong Xie</name></author><author><name sortKey="Guo, Zhihong" sort="Guo, Zhihong" uniqKey="Guo Z" first="Zhihong" last="Guo">Zhihong Guo</name></author></analytic><series><title level="j">Journal of virology</title><idno type="ISSN">0022-538X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Viral (blood)</term><term>Antigens, Viral (immunology)</term><term>B-Lymphocytes (immunology)</term><term>Epitope Mapping</term><term>Hong Kong</term><term>Humans</term><term>Immunodominant Epitopes</term><term>Membrane Glycoproteins (immunology)</term><term>Middle Aged</term><term>Neutralization Tests</term><term>Nucleocapsid Proteins (immunology)</term><term>Peptide Library</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Nonstructural Proteins</term><term>Viral Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (sang)</term><term>Antigènes viraux (immunologie)</term><term>Banque de peptides</term><term>Cartographie épitopique</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Hong Kong</term><term>Humains</term><term>Lymphocytes B (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines nucléocapside (immunologie)</term><term>Protéines virales (immunologie)</term><term>Protéines virales non structurales</term><term>Sujet âgé</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term><term>Épitopes immunodominants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Membrane Glycoproteins</term><term>Nucleocapsid Proteins</term><term>Viral Envelope Proteins</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Hong Kong</term><term>Immunodominant Epitopes</term><term>Peptide Library</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Nonstructural Proteins</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term><term>Glycoprotéines membranaires</term><term>Lymphocytes B</term><term>Protéines de l'enveloppe virale</term><term>Protéines nucléocapside</term><term>Protéines virales</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>B-Lymphocytes</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Epitope Mapping</term><term>Humans</term><term>Middle Aged</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Banque de peptides</term><term>Cartographie épitopique</term><term>Glycoprotéine de spicule des coronavirus</term><term>Hong Kong</term><term>Humains</term><term>Protéines virales non structurales</term><term>Sujet âgé</term><term>Tests de neutralisation</term><term>Épitopes immunodominants</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Hong Kong</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel strain of coronavirus. Examination of the immune responses of patients who have recovered from SARS should provide important information for design of a safe and effective vaccine. We determined the continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS patients through biopanning with a vast M13 phage display dodecapeptide library. These epitopes converged to very short peptide fragments, one on each of the structural proteins spike and nucleocapsid and the nonstructural proteins 3a, 9b, and nsp 3. Immunoassays found that most of the patients who had recovered from SARS developed complementary antibodies to the epitope-rich region on the spike S2 protein, indicating that this is an immunodominant site on the viral envelope comprising the spike, matrix, and small envelope glycoproteins. These S2-targeting antibodies were shown to effectively neutralize the coronavirus, indicating that they provided protective immunity to help the patients recover from the viral infection. These results suggest that the SARS coronavirus might have an antigenic profile distinct from those of other human or animal coronaviruses. Due to the tested safety and protective effects of the convalescent-phase serological antibodies, identification of their complementary antigens may enable the design of an epitope-based vaccine to prevent potential antibody-mediated immunopathology.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15731234</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN><JournalIssue CitedMedium="Print"><Volume>79</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.</ArticleTitle><Pagination><MedlinePgn>3401-8</MedlinePgn></Pagination><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel strain of coronavirus. Examination of the immune responses of patients who have recovered from SARS should provide important information for design of a safe and effective vaccine. We determined the continuous viral epitopes targeted by antibodies in plasma samples from convalescent SARS patients through biopanning with a vast M13 phage display dodecapeptide library. These epitopes converged to very short peptide fragments, one on each of the structural proteins spike and nucleocapsid and the nonstructural proteins 3a, 9b, and nsp 3. Immunoassays found that most of the patients who had recovered from SARS developed complementary antibodies to the epitope-rich region on the spike S2 protein, indicating that this is an immunodominant site on the viral envelope comprising the spike, matrix, and small envelope glycoproteins. These S2-targeting antibodies were shown to effectively neutralize the coronavirus, indicating that they provided protective immunity to help the patients recover from the viral infection. These results suggest that the SARS coronavirus might have an antigenic profile distinct from those of other human or animal coronaviruses. Due to the tested safety and protective effects of the convalescent-phase serological antibodies, identification of their complementary antigens may enable the design of an epitope-based vaccine to prevent potential antibody-mediated immunopathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Xiaofen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Huanghao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zu-Feng</ForeName><Initials>ZF</Initials></Author><Author ValidYN="Y"><LastName>Sin</LastName><ForeName>Wan-Yee Fion</ForeName><Initials>WY</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Junjie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Chun-Kit Gannon</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chak-Sum Samuel</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yanzhen</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Shuyong</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tin-Yau</ForeName><Initials>TY</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Sik-To</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zhihong</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487105">3a protein, severe acute respiratory syndrome coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C087633">nonstructural protein, coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016056" MajorTopicYN="Y">Immunodominant Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019151" MajorTopicYN="N">Peptide Library</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15731234</ArticleId><ArticleId IdType="pii">79/6/3401</ArticleId><ArticleId IdType="doi">10.1128/JVI.79.6.3401-3408.2005</ArticleId><ArticleId IdType="pmc">PMC1075701</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Immunol. 2000 Aug 15;165(4):2278-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10925317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 Feb;66(2):956-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1309922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2003 Jun;9(3):199-201</Citation><ArticleIdList><ArticleId IdType="pubmed">12777656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2003 May;2(5):346-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12775768</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Yi Xue Za Zhi. 2003 Jun 25;83(12):1018-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12899773</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 Oct 1;21(27-30):4095-104</Citation><ArticleIdList><ArticleId IdType="pubmed">14505885</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2003 Dec;49(12):1989-96</Citation><ArticleIdList><ArticleId IdType="pubmed">14633869</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Nov 28;302(5650):1504-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14645828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2004 Jan;11(1):227-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14715574</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2542-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14983045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 Nov;66(11):6695-705</Citation><ArticleIdList><ArticleId IdType="pubmed">1383568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1993 Apr;74 ( Pt 4):745-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7682252</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 May;69(5):2858-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7707508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Dec;69(12):8127-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7494335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2004 Jun;50(6):988-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15054081</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Vet Res. 1980 Jun;41(6):868-76</Citation><ArticleIdList><ArticleId IdType="pubmed">6254400</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Vet Res. 1981 Mar;42(3):382-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6267961</ArticleId></ArticleIdList></Reference><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1990 Jun;71 ( Pt 6):1313-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1693663</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Vet Res. 2001 Jul;65(3):137-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11480517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002875 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002875 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15731234
|texte= B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15731234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |